KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Receivables - Other: 2017-2023

Historic Receivables - Other for BeOne Medicines (ONC) over the last 7 years, with Dec 2023 value amounting to $1.7 million.

  • BeOne Medicines' Receivables - Other fell 42.91% to $1.7 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.7 million, marking a year-over-year decrease of 42.91%. This contributed to the annual value of $1.7 million for FY2023, which is 42.91% down from last year.
  • According to the latest figures from FY2023, BeOne Medicines' Receivables - Other is $1.7 million, which was down 42.91% from $3.0 million recorded in FY2022.
  • BeOne Medicines' Receivables - Other's 5-year high stood at $12.7 million during FY2020, with a 5-year trough of $1.7 million in FY2023.
  • In the last 3 years, BeOne Medicines' Receivables - Other had a median value of $3.0 million in 2022 and averaged $3.3 million.
  • In the last 5 years, BeOne Medicines' Receivables - Other plummeted by 77.57% in 2019 and then soared by 554.81% in 2020.
  • Yearly analysis of 5 years shows BeOne Medicines' Receivables - Other stood at $1.9 million in 2019, then soared by 554.81% to $12.7 million in 2020, then slumped by 60.07% to $5.1 million in 2021, then tumbled by 39.85% to $3.0 million in 2022, then tumbled by 42.91% to $1.7 million in 2023.